Latest / The Buyout Show with Fexingo: Private Equity, Roll-Ups, and Business Acquisitions / How Private Equity Is Buying Up Hearing Aid Practices
Transcript
- Lucas: Luna, I want to talk about something that's probably happening right now in a strip mall near you—private equity is quietly buying up hearing aid practices. Luna: Hearing aids? I mean, I know the population is aging, but is this a big enough market for PE firms to get excited about? Lucas: It's bigger than you think. The U.S. hearing aid market is about $8 billion annually. And it's been incredibly fragmented—mostly independent audiologists running one or two clinics. That's exactly the kind of structure PE loves: low consolidation, steady cash flow, demographic tailwinds. Luna: And there's a clear demographic driver—the baby boomer generation is now in their 70s and 80s. Hearing loss becomes almost universal past a certain age. Lucas: Exactly. So firms are rolling up these practices, creating platforms. One example is Audiology Holdings, LLC. Between 2020 and 2025, they acquired 47 independent practices across the Midwest and Southeast. Lucas: Before we go deeper—I want to mention something important about how this show works. We don't run ads. No sponsors interrupting the conversation. The show exists because of listeners who chip in. If you get value from these episodes, the best way to support us is at buy me a coffee dot com slash fexingo. It keeps us independent and ad-free. Luna: Yeah, it's a small gesture that makes a real difference for us. And it means we never have to tailor the content to please a sponsor. Lucas: Right. So back to hearing aids. Audiology Holdings is a classic PE roll-up. They buy a practice for around 6 to 8 times EBITDA—usually between $2 million and $5 million per clinic—and then immediately centralize back-office functions: billing, insurance credentialing, purchasing. Luna: And that's where the margin improvement comes from. Independent audiologists spend a huge chunk of their time on paperwork. Consolidating that frees them up to see more patients. Lucas: Exactly. The second lever is purchasing power. Hearing aids are manufactured by just a handful of global players: Sonova, Demant, WS Audiology, GN Hearing. When you're buying 10,000 devices a year instead of 200, you can negotiate 15 to 20 percent discounts. Luna: So the PE firm makes money on procurement and efficiency. But what about the patient? Does the quality of care change? Lucas: That's the critical question. The pitch from firms like Audiology Holdings is that they can invest in better diagnostic equipment, offer longer warranties, and provide more consistent follow-up care. But critics argue that once a practice is owned by a PE firm, audiologists are pushed to sell higher-margin devices and meet revenue targets. Luna: And then there's the OTC hearing aid regulation that took effect in 2022. The FDA allowed hearing aids to be sold over the counter without a prescription. That created a new competitive threat from companies like Apple and Bose. Lucas: Right. The OTC market was supposed to disrupt the traditional model. But honestly, adoption has been slower than expected. The devices are less powerful, and many consumers still want a professional fitting, especially for moderate to severe hearing loss. So the traditional clinic model still has strong defensibility. Lucas: Another angle is insurance. Medicare doesn't cover hearing aids, but Medicare Advantage plans increasingly include hearing benefits. Those plans contract with provider networks. A pe backed roll-up can negotiate better reimbursement rates as a group than a solo practitioner. Luna: So PE is basically positioning these clinics to capture the coming wave of insured patients. It's a bet on reimbursement expansion. Lucas: Yes. The average hearing aid costs about $2,300 per ear. With insurance covering part of that, demand should rise. And the demographic tailwind is undeniable: by 2030, 1 in 5 Americans will be over 65. Luna: But I've heard that margins in audiology are not that high. Independent practices often run at 10 to 15 percent EBITDA margins. After PE leverage and centralization costs, does the math work? Lucas: It works if they can drive margins to 20 percent or more. And the track record suggests they can. Audiology Holdings, for example, reportedly improved margins from 12 to 18 percent within two years. The key is scale—once you have 30 or 40 clinics under one roof, the back-office savings compound. Luna: And what about exit strategies? Is this a platform for a larger strategic buyer down the line, or do they aim for an IPO? Lucas: Most likely a sale to a larger PE firm or a healthcare services company. There have been a few large acquisitions in the space already. In 2024, Demant acquired a 40-clinic network in Texas for about $200 million. That's a nice exit for the PE sponsor that built it. Lucas: But there's a risk: the industry is still relatively small. A roll-up of 100 clinics is less than 5 percent of the total U.S. market. So PE firms have to be patient—it's not going to transform overnight. Luna: And there's the regulatory risk. If Medicare ever decides to cover hearing aids, the government would likely impose price controls. That could squeeze margins. Lucas: That's a real possibility. But for now, the tailwinds are strong. The baby boomer wave is cresting, and hearing loss prevalence rises sharply after age 70. About one in three people over 65 and half over 75 have significant hearing loss. That's a massive addressable market. Luna: So when I walk into my local hearing aid clinic next time, should I expect to see a private equity logo on the door? Lucas: Maybe not a logo, but there's a good chance it's owned by a pe backed platform. The trend is accelerating. We're seeing similar roll-ups in audiology as we've seen in dental, veterinary, and physical therapy. It's the same playbook applied to a new vertical. Luna: And what does that mean for the audiologist who used to own the practice? They often stay on as employees, maybe with an earn-out. Some love it because they can focus on patient care without the business headaches. Others hate losing autonomy. Lucas: It's a mixed bag. But the consolidation is happening, whether we like it or not. The question for listeners is: when you need a hearing aid, will you go to the independent clinic down the street or the pe backed chain? And will you even know the difference? Lucas: I think the answer is that in five years, most of those independent clinics will be part of a larger network. The economics are just too compelling for the owners to say no to a buyout offer at 7 times EBITDA. Luna: And with interest rates coming down from their 2023 highs, the cost of debt financing is more attractive again. That will probably accelerate deal flow in 2026 and 2027. Lucas: Exactly. So hearing aid roll-ups are a quiet but steady part of the private equity landscape. Not as flashy as tech buyouts, but with reliable returns. Thanks for listening to The Buyout Show.